Physician profile
Sameer Veerani
NPI 1457807802
$2,089.18
in general payments reported to CMS, 2019-2025
16 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $402 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995 · Education: $94.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.54 |
| Education | $94.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $843.49 | 2024-2025 | |
| Janssen Biotech, INC. | $242.60 | 2024-2025 | Tremfya |
| Genzyme Corporation | $151.85 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.65 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Evoke Pharma, INC. | $124.99 | 2025 | |
| Intercept Pharmaceuticals, INC. | $98.82 | 2025 | |
| Aimmune Therapeutics, INC. | $94.51 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $84.50 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $70.82 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $54.16 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $46.51 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $44.52 | 2024 | |
| Madrigal Pharmaceuticals | $23.63 | 2024 | Resmetirom |
| Janssen Pharmaceuticals, INC | $19.98 | 2024 | Spravato |
| Braintree Laboratories, INC. | $19.88 | 2025 | Sutab |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.27 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Veerani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.